DexCom, Inc. $DXCM Position Trimmed by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 37.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,439,689 shares of the medical device company’s stock after selling 872,521 shares during the quarter. Westfield Capital Management Co. LP’s holdings in DexCom were worth $95,552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CVA Family Office LLC grew its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. ORG Partners LLC grew its stake in shares of DexCom by 124.3% in the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares in the last quarter. Spire Wealth Management grew its stake in shares of DexCom by 113.8% in the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares in the last quarter. Aventura Private Wealth LLC bought a new stake in shares of DexCom in the 4th quarter valued at approximately $43,000. Finally, Rothschild Investment LLC grew its stake in shares of DexCom by 59.9% in the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after buying an additional 245 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $59.91, for a total value of $101,847.00. Following the transaction, the executive vice president owned 109,504 shares in the company, valued at $6,560,384.64. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 32,871 shares of company stock worth $2,306,638. 0.28% of the stock is owned by corporate insiders.

DexCom Stock Performance

DexCom stock opened at $72.59 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The stock has a fifty day moving average price of $64.71 and a two-hundred day moving average price of $66.94. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The firm has a market capitalization of $28.01 billion, a P/E ratio of 31.02, a P/E/G ratio of 1.14 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company posted $0.32 earnings per share. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on DXCM shares. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Canaccord Genuity Group set a $82.00 price target on DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. Barclays reissued an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a report on Tuesday, March 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $82.42.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.